KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Astrazeneca (AZN) Non-Current Deferred Tax Liability (2016 - 2025)

Historic Non-Current Deferred Tax Liability for Astrazeneca (AZN) over the last 17 years, with Q4 2025 value amounting to -$3.5 billion.

  • Astrazeneca's Non-Current Deferred Tax Liability fell 590.02% to -$3.5 billion in Q4 2025 from the same period last year, while for Dec 2025 it was -$3.5 billion, marking a year-over-year decrease of 590.02%. This contributed to the annual value of -$3.5 billion for FY2025, which is 590.02% down from last year.
  • According to the latest figures from Q4 2025, Astrazeneca's Non-Current Deferred Tax Liability is -$3.5 billion, which was down 590.02% from -$3.6 billion recorded in Q3 2025.
  • In the past 5 years, Astrazeneca's Non-Current Deferred Tax Liability ranged from a high of $6.2 billion in Q4 2021 and a low of -$6.4 billion during Q3 2021
  • Its 5-year average for Non-Current Deferred Tax Liability is -$2.5 billion, with a median of -$3.3 billion in 2024.
  • Per our database at Business Quant, Astrazeneca's Non-Current Deferred Tax Liability skyrocketed by 37726.83% in 2021 and then crashed by 21620.96% in 2024.
  • Over the past 5 years, Astrazeneca's Non-Current Deferred Tax Liability (Quarter) stood at $6.2 billion in 2021, then plummeted by 52.56% to $2.9 billion in 2022, then decreased by 3.4% to $2.8 billion in 2023, then tumbled by 216.21% to -$3.3 billion in 2024, then decreased by 5.9% to -$3.5 billion in 2025.
  • Its last three reported values are -$3.5 billion in Q4 2025, -$3.6 billion for Q3 2025, and -$3.6 billion during Q2 2025.